Medivir AB - Product Pipeline Review – 2015 Now Available at iData Insights rect s, Medivir AB - Product Pipeline Review - 2015 , provides an overview of the Medivir AB s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Medivir AB s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Medivir AB including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Medivir AB s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Medivir AB s pipeline products Reasons to buy - Evaluate Medivir AB s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Medivir AB in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Medivir AB s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps Develop strategic initiatives by understanding the focus areas of Medivir AB and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Medivir AB - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Medivir AB and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landing-
page.php?id=124194/medivir-ab-product-pipeline-review-2015 To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landing-
page.php?id=124194/medivir-ab-product-pipeline-review-2015 Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Medivir AB Snapshot 5 Medivir AB Overview 5 Key Information 5 Key Facts
1
5 Medivir AB
Research and Development Overview
6 Key Therapeutic Areas 6 Medivir AB
Pipeline Review
8 Pipeline Products by Stage of Development 8 Pipeline Products 9 Pipeline Products
Monotherapy
Partnered Products
10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products
Out-Licensed Products
12 Out-Licensed Products/Combination Treatment Modalities 13 Medivir AB
Pipeline Products Glance
14 Medivir AB
Clinical Stage Pipeline Products
14 Phase I Products/Combination Treatment Modalities 14 Medivir AB
Early Stage Pipeline Products
15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Medivir AB
Drug Profiles
17 AL-704 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 MIV-711 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 BK-1361 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 MIV-150 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 MIV-802 22 Product Description
2
22 Mechanism of Action 22 R&D Progress 22 Small Molecule to Inhibit HIV Protease for HIV Infection 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecules to Inhibit DNA Polymerase for Hepatocellular Carcinoma 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecules to Inhibit Proteases for Infectious Diseases 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Medivir AB
Pipeline Analysis
27 Medivir AB
Pipeline Products by Target
27 Medivir AB
Pipeline Products by Route of Administration
28 Medivir AB
Pipeline Products by Molecule Type
29 Medivir AB
Pipeline Products by Mechanism of Action
30 Medivir AB
Recent Pipeline Updates
31 Medivir AB
Dormant Projects
33 Medivir AB
Discontinued Pipeline Products
34 Discontinued Pipeline Product Profiles 34 lagociclovir 34 MIV-150 34 MIV-701 34 Small Molecule to Inhibit NS5A for Hepatitis C 34 TMC-649128 35 Medivir AB
Locations And Subsidiaries
36 Head Office
3
36 Other Locations & Subsidiaries 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us Read More @ http://www.idatainsights.com/reports-landing-page.php?id=124194/medivir-ab-product-
pipeline-review-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
Contact Us: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com
About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.
4